Related Experiment Video
Updated: Jul 4, 2026
09:51
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Toll-like receptor 7 agonists and skin
Natalija Novak1, Chun-Feng Yu, Thomas Bieber
1Department of Dermatology and Allergy, University of Bonn, Bonn, Germany. Natalija.Novak@ukb.uni-bonn.de
Drug News & Perspectives
|June 19, 2008
Summary
Toll-like receptor (TLR) 7 agonists, like imiquimod, activate innate immunity to treat skin conditions. This review explores TLR7
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Toll-like receptor (TLR) 7 is an intracellular receptor recognizing pathogen-derived nucleosides/nucleotides.
- TLR7 agonists, including imiquimod, activate innate immune responses.
- Targeting TLR pathways offers a promising therapeutic strategy for various diseases.
Purpose of the Study:
- To review the immunological mechanisms of TLR7 agonists, focusing on imiquimod.
- To summarize established clinical therapies involving TLR7 agonists.
- To explore potential future applications of TLR7 agonists in medicine.
Main Methods:
- Review of existing literature on TLR7 agonists and their clinical applications.
- Analysis of immunological mechanisms triggered by imiquimod.
- Summary of current therapeutic uses and future prospects of TLR7 agonists.
Main Results:
- Imiquimod, a TLR7 agonist, is approved for treating genital warts and skin cancers.
- Topical imiquimod induces interferon-alpha, IL-12, TNF-alpha, and a Th1 immune response.
- Imiquimod enhances dendritic cell and T cell recruitment and function.
Conclusions:
- TLR7 agonists, particularly imiquimod, demonstrate significant immunomodulatory effects.
- Imiquimod's multifaceted actions support its use in various dermatological conditions.
- Further research into TLR7 agonists may reveal novel therapeutic applications.
Related Concept Videos
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:26Signal Transduction: Overview
Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Typically, signal transduction involves three...
01:30Transducer Mechanism: G Protein–Coupled Receptors
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical, 7TM, or...
GPCRs are also called heptahelical, 7TM, or...